Intervention Protocol

You have free access to this content

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

  1. Kelvin KW Chan1,*,
  2. Anne-Marie Glenny2,
  3. Susan Furness2,
  4. Helen V Worthington2

Editorial Group: Cochrane Oral Health Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD010341


How to Cite

Chan KKW, Glenny AM, Furness S, Worthington HV. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD010341. DOI: 10.1002/14651858.CD010341.

Author Information

  1. 1

    Princess Margaret Hospital, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

  2. 2

    School of Dentistry, The University of Manchester, Cochrane Oral Health Group, Manchester, UK

*Kelvin KW Chan, Sunnybrook Odette Cancer Centre, Princess Margaret Hospital, 2075 Bayview Avenue, Toronto, Ontario, M4N3M5, Canada. kelvin.chan@sunnybrook.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objectives

  • To determine whether molecularly targeted therapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival, locoregional control and reduced recurrence.

  • To determine whether immunotherapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival, locoregional control and reduced recurrence.

Secondary objectives

  • To determine whether molecularly targeted therapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity oropharyngeal cancers are associated with increased quality of life, harm, costs and patient satisfaction.

  • To determine whether immunotherapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers are associated with increased quality of life, harm, costs and patient satisfaction.